Publications
2008 - 2010
Cheifetz AS, Stern J, Garud S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. J Clin Gastroenterol. 2010 Jul 27.PMID: 20679905.
Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. PubMed PMID: 20451665.
Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, Cheifetz AS. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis – a prospective study. J Crohn’s Colitis 2010 Jun; 4 (2): 171-175.
Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M, Kalluri R.Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem. 2010 Jun 25;285(26):20202-12 PubMed PMID: 20363741.
Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opin Drug Saf. 2010 Jul;9(4):573-92. PubMed PMID: 20377475.
Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Rev Clin Immunol. 2010 Jul;6(4):521-6. PubMed PMID: 20594123.
Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: Pathogen or innocent bystander? Inflamm Bowel Dis. 2010 Mar 15. PubMed PMID: 20232408.
Moss AC. CMV in moderately active colitis: much ado about nothing? Dig Dis Sci. 2010 Apr;55(4):880-2. PubMed PMID: 20204696.
Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther. 2010 Apr;31(8):802-9. PubMed PMID: 20055785.
Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Aug;16(8):1393-6. PubMed PMID: 19998457.
Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006873. PubMed PMID: 19821389.
Cury DB, Moss AC, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm Bowel Dis. 2010 May;16(5):723-4. PubMed PMID: 19728388.
Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):395-405. PubMed PMID: 19673626.
Garad,S,Peppercorn,MA. Ulcerative colitis:current treatment strategies and future prospects. Therapeutic Advances in Gastroenterology 2009;2:99-108.
Fernandez-Becker N, Moss AC. In silico analysis of T-bet activity in peripheral blood mononuclear cells in patients with inflammatory bowel disease (IBD). In Silico Biology 2009 September 9th (in press).
Doherty GA, Cheifetz AS. Targeting TNF in postoperative recurrence of Crohn's disease: Can we extinguish the fire before it starts? Inflamm Bowel Dis. 2009 May 21;15(12):1925-1926. PubMed PMID: 19462427.
Tukey M, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol. 2009 Nov;104(11):2734-9. PubMed PMID: 19584828.
Lawlor GO, Moss AC. Cause for Controversy? Infliximab in the treatment of ulcerative colitis: An update. Clin Exp Gastroenterology 2009 October 12th (in press).
Doherty,GA,Peppercorn,MA.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Clinical and Experimental Gastroenterology 2009;2:139-47.
Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010 May;55(5):1413-20. PubMed PMID: 19533357.
Patil SA, Moss AC. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):177-84. PubMed PMID: 19072352.
Zandman DB, Peppercorn MA. Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine. Patient Prefer Adherence. 2009 Nov 3;3:87-92. PubMed PMID: 19936149.
Moss AC, Cheifetz AS. How often is a diagnosis of ulcerative colitis changed to Crohn's disease and vice versa? Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S155-6. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47. PubMed PMID: 18816774.
Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O'Brien M, Maratos-Flier E, Pothoulakis C. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10613-8. PubMed PMID: 18650383.
Mehta BP, Shmerling RH, Moss AC. Pseudogout after polyethylene glycol bowel cleansing. J Clin Gastroenterol. 2009 Jan;43(1):95-6. PubMed PMID: 18528291.
Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther. 2008 Jul;28(2):221-7. PubMed PMID: 18485127.
Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008;68(8):1089-103 PubMed PMID: 18484800.
Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68(9):1157-67. PubMed PMID: 18547130.
Hu MY, Peppercorn MA. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2008 Apr;9(6):1049-58. PubMed PMID: 18377346.
Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008 Mar;52(3):1121-6. PubMed PMID: 18195066.
